These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2525367)

  • 21. [Acute myeloid leukemia after treatment of Hodgkin's disease].
    Carneiro PC; Pereira ED; Mitteldorf CS; Martinez GA; Beitler B; Pozzi DH
    Rev Hosp Clin Fac Med Sao Paulo; 1989; 44(2):87-90. PubMed ID: 2616992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CCNU, vinblastine, procarbazine and prednisone (CVPP) with extended-field radiotherapy in the treatment of early unfavorable Hodgkin's disease. A prospective study on behalf of the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Gobbi PG; Pieresca C; Cavanna L; Corbella F; Vallisa D; Federico M; Formisano R; Carotenuto M; Merli F; Callea V; Angrilli F; Silingardi V
    Haematologica; 1996; 81(6):503-12. PubMed ID: 9009437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma and leukocytic bactericidal activity in the course of chemotherapy of Hodgkin's disease.
    Wysocka J; Kemona H; Prokopowicz J; Kiluk S
    Acta Med Pol; 1987; 28(1-4):99-107. PubMed ID: 3506375
    [No Abstract]   [Full Text] [Related]  

  • 24. [Chemotherapy of stage III-IV Hodgkin's disease. A retrospective analysis of the 53 cases collected from 9 institutions in Japan].
    Takagi T; Ohnoshi T; Hayashi K; Ohtake S; Sampi K; Sawada U; Kuraishi Y; Kondo M; Suzuki H; Oyama A
    Rinsho Ketsueki; 1989 Jul; 30(7):994-8. PubMed ID: 2681883
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hodgkin's disease in children; treatment results with or without radiotherapy].
    Behrendt H
    Ned Tijdschr Geneeskd; 1986 May; 130(19):865-8. PubMed ID: 3754935
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical features and treatment of Hodgkin's disease].
    Shirakawa S; Kita K; Kobayashi T; Ohno T
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):421-34. PubMed ID: 3754108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Should MOPP-ABVD alone be standard for childhood Hodgkin's?
    Constine LS
    J Clin Oncol; 1998 Mar; 16(3):1235. PubMed ID: 9508214
    [No Abstract]   [Full Text] [Related]  

  • 31. [Acute lymphoblastic leukemia L3 in Hodgkin's disease in remission: primary or secondary leukosis?].
    Musto P; Lucchi T; Barbieri D; Ferraresi P; Lanza F
    Recenti Prog Med; 1985 Apr; 76(4):194-8. PubMed ID: 3862191
    [No Abstract]   [Full Text] [Related]  

  • 32. MOPP, ABVD, or both to treat Hodgkin's disease.
    Martino R; Nomdedeu J; Brunet S
    N Engl J Med; 1993 Apr; 328(14):1045; author reply 1045-6. PubMed ID: 7680766
    [No Abstract]   [Full Text] [Related]  

  • 33. [Hodgkin's disease with systemic vasculitis and Lambert-Eaton myasthenic syndrome--case report].
    Homenda W; Hellmann A
    Wiad Lek; 2000; 53(9-10):574-8. PubMed ID: 11148928
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peripheral T-cell non-Hodgkin's lymphoma following treatment of nodular lymphocyte predominance Hodgkin's disease.
    Rysenga E; Linden MD; Carey JL; Ross CW; Schnitzer B; Sawdyk M; Maeda K
    Arch Pathol Lab Med; 1995 Jan; 119(1):88-91. PubMed ID: 7802562
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
    Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
    Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hodgkin's disease, splenectomy and secondary leukemia.
    Centurioni R; Brianzoni F; Leoni P; Danieli G
    Haematologica; 1993; 78(4):258-9. PubMed ID: 8294062
    [No Abstract]   [Full Text] [Related]  

  • 37. A rare opportunity to observe aspects of the natural history of untreated Hodgkin's disease.
    Haines IE; Schwarz MA
    Med J Aust; 1986 Jun; 144(12):652-4. PubMed ID: 3754928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy responsive collagenous colitis in a patient with Hodgkin's disease: a possible paraneoplastic phenomenon.
    van der Werf SD; van Berge Henegouwen GP; Bronkhorst FB; Werre JM
    Neth J Med; 1987 Dec; 31(5-6):228-33. PubMed ID: 3431617
    [No Abstract]   [Full Text] [Related]  

  • 39. [Lung fibrosis after bleomycin therapy].
    Kozielski J; Rauer R; Ziora D; Spychałowicz W
    Pneumonol Alergol Pol; 1994; 62(9-10):520-5. PubMed ID: 7532510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents.
    Müller LJ; Moorer-van Delft CM; Zijl R; Roubos EW
    Cancer Res; 1990 Mar; 50(6):1924-8. PubMed ID: 2407348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.